BMO Capital lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $43.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change FDA

Coherus Biosciences (CHRS) PT Lowered to $24 at Credit Suisse; Neulasta Biosimilar CRL Poses Greater Risk for CHS-1701June 14, 2017 9:10 AM Coherus Biosciences (CHRS) Neulasta Biosimilar Delay 'Appears Resolvable' - CowenJune 12, 2017 12:29 PM Coherus Biosciences (CHRS) PT Lowered to $37 at Baird Following FDA Letter June 12, 2017 11:33 AM Coherus BioSciences (CHRS) Receives CRL from FDA for CHS-1701 BLAJune 12, 2017 6:38 AM